Weill Cornell Medicine scientists have built the first global database of clinical trials testing a rapidly expanding approach to cancer treatment that involves genetically modifying immune cells to recognize specific targets on a patient’s cancer cells and attack them. By analyzing the approach, called chimeric antigen receptor (CAR) therapies, the scientists designed a “therapeutic roadmap” that identifies all current therapies as well as additional cancers that can be treated with them....
